With tech from Spin­raza­'s mak­er, French start­up Dy­nacure gets $55M to tack­le neu­ro­mus­cu­lar dis­ease

Drug dis­cov­ery pow­er­house Io­n­is gave Bio­gen one of its biggest wins in re­cent times with the de­liv­ery of Spin­raza, the spinal mus­cu­lar at­ro­phy drug ex­pect­ed to de­liv­er $750 mil­lion in sales this year. Since its Spin­raza days, Io­n­is has churned out promis­ing pro­gram af­ter promis­ing pro­gram, ce­ment­ing its rep­u­ta­tion for de­liv­er­ing clin­i­cal as­sets to its part­ners.

Now, a col­lab­o­ra­tion be­tween Io­n­is and a re­search in­sti­tute in France has laid the foun­da­tion for a start­up that’s tack­ling an­oth­er neu­ro­mus­cu­lar dis­or­der. This time, they’re shoot­ing to de­vel­op a drug for cen­tronu­clear my­opa­thy, a con­di­tion char­ac­ter­ized by mus­cle wast­ing and mus­cle weak­ness. And a group of in­vestors led by An­dera Part­ners (for­mer­ly Ed­mond de Roth­schild In­vest­ment Part­ners) has ponied up $55 mil­lion to sup­port the re­search.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.